| Similar Articles |
|---|
 |
Chemistry World
October 23, 2014
Rebecca Trager |
US agency fast-tracks Ebola vaccine development The US Department of Health and Human Services is fast-tracking tests on an Ebola vaccine by providing $5.8 million under a one-year contract with the Maryland-based biotech company Profectus BioSciences   |
Chemistry World
August 5, 2015
Emma Stoye |
Vaccine raises hopes of an end to Ebola A Phase III trial for a candidate Ebola vaccine has shown extremely encouraging results in Guinea, demonstrating complete protection for all those who were vaccinated. |
Chemistry World
January 19, 2015
Maria Burke |
Roadmap to fast track Ebola vaccine development A global group of experts has developed a 'roadmap' to help the health community fast track an Ebola vaccine. |
Chemistry World
September 1, 2014
Maria Burke |
Experimental Ebola drug 'impressive' in animal trials In the hunt for a treatment for Ebola, a new study has shown that monkeys given the experimental drug ZMapp all survived infection with the virus. |
Chemistry World
January 29, 2015
Matthew Gunther |
Ebola vaccine shown to be safe in humans GlaxoSmithKline's experimental Ebola vaccine is capable of triggering an immune response in humans, according to a new study. |
Chemistry World
August 20, 2014
Maria Burke |
Doctors turn to experimental Ebola treatments The emergency use of an experimental medicine is highly unusual, but the WHO has declared the Ebola outbreak a public health emergency of international concern. |
Popular Mechanics
September 2006
Ben Harder |
Seeking Immunity Pathogens like West Nile virus show no respect for borders. But a new class of vaccines may soon keep them in check. |
Chemistry World
February 9, 2007
Victoria Gill |
Africa's First Large-Scale HIV Vaccine Trial The first large-scale clinical trial of an HIV vaccine will involve around 3000 participants in five selected sites in South Africa. It will compare the effectiveness of the vaccine at reducing HIV infection compared to a placebo. |
Chemistry World
July 29, 2015
Maria Burke |
Malaria vaccine approval first marred by efficacy question mark After decades of research, a malaria vaccine has finally been given the green light by a regulatory agency. But with limited efficacy and questions over the vaccine's cost, its future remains unclear. |
Pharmaceutical Executive
October 1, 2014
Jill Wechsler |
Ebola Crisis Challenges Pharma R&D Companies gain support and pressure to deliver new treatments for spreading outbreak. |
Wired
January 2003
Richard Martin |
Testing the First AIDS Vaccine Medical establishment, government, and Genentech be damned -- Don Francis has never stopped believing. Now he's about to finish testing the first human AIDS vaccine. |
| AskMen.com |
Vaccine Helps Prevent HIV For the first time, an experimental vaccine has prevented infection with the AIDS virus, a watershed event in the deadly epidemic and a surprising result. |
Pharmaceutical Executive
December 1, 2005
Anthony Tao |
The Avian Few: Is it Too Late for Pharma to Re-enter the Vaccine Fray? Small profit margins and high litigation risks drove most companies out of the vaccine business decades ago. As a possible pandemic looms, pharma re-enters the fray. Is it too late? |
Chemistry World
October 9, 2013
Phillip Broadwith |
GSK to apply for malaria vaccine approval Preliminary results from the first ever Phase III clinical trial of a malaria vaccine show that it can reduce malaria infections in vaccinated children over 18 months. |
The Motley Fool
September 25, 2007
Brian Orelli |
Cold HIV Vaccine Gets Frozen Phase 2 clinical trials of Merck's HIV vaccine were frozen, leaving the door open for other drugmakers that have vaccines of their own in early trials. Investors, take note. |
Pharmaceutical Executive
December 1, 2010
Walter Armstrong |
Vaccines: Progress in Preventing Bad Bugs Long on the sidelines of pharma R&D, vaccine development is moving to center stage as most of the big pharmas diversify, spreading their risk among the full gamut of revenue sources. |
Chemistry World
September 26, 2007
Victoria Gill |
HIV Vaccines 'Will Not Work' Just days after US drug firm Merck revealed its leading HIV vaccine candidate had flopped in clinical trials, a leading immunologist has predicted that many other vaccines in the pipeline will also fail because their design is similarly flawed. |
Chemistry World
July 8, 2010
Sarah Houlton |
Antibodies spark HIV vaccine hopes These cross-reactive broadly neutralising antibodies bound to and neutralised more than 90 per cent of the HIV strains they were tested against. |
The Motley Fool
July 25, 2007
Brian Orelli |
Hopeful Flu Production Technology From Baxter While the clinical trial demonstrating strong immunogenicity for the new vaccine is certainly good news, the continued development of the production technology is probably the more important item for investors. |
Chemistry World
August 4, 2008
Pete Mitchell |
Vaccine failures shake up HIV research Prospects for an HIV vaccine have receded with the July decision by the US government National Institutes of Health (NIH) to cancel trials of its main vaccine candidate. |
Chemistry World
September 3, 2009
Sarah Houlton |
New HIV vaccine hope A team of scientists in the US has discovered two new antibodies that could lead to an HIV vaccine. |
Fast Company
Sarah Kessler |
Why There Is No Available Ebola Vaccine Ebola has the unprofitable qualities of being both relatively rare and infecting a mostly poor population. No pharma company wanted to foot the bill for human trials and production. |
Scientific American
April 10, 2006
Christine Soares |
Turning Yellow Yellow fever shot confers long-lasting immunity, a trait that medical researchers hope to transfer to other kinds of vaccines. |
Chemistry World
April 23, 2015
Tim Wogan |
SiRNA treatment cures Ebola in monkeys The first laboratory trial demonstrating the effectiveness of an experimental drug against the strain of Ebola currently ravaging West Africa has been performed in rhesus monkeys. |
Fast Company
August 8, 2011
Kate Rockwood |
AIDS Vaccine Conference Despite billions in annual research dollars, the quest for an AIDS vaccine remains elusive. |
The Motley Fool
January 11, 2005
Charly Travers |
The Future of Cancer Vaccines Biotech companies developing cancer vaccines have been in investors' doghouses for a long time. Can a vaccine help stave off forms of the disease? |
The Motley Fool
September 24, 2009
Brian Orelli |
Drugmakers' HIV Treatments Live On Companies that make HIV drugs could lose billions of dollars in revenue if an effective vaccine is developed. All drug-company investors need to keep an eye on up-and-coming drugs from competitors that could take market share. |
BusinessWeek
November 29, 2004
Kerry Capell |
"A Vaccine Every Woman Should Take" Two drug companies are closing in on shots against HPV, the leading cause of cervical cancer. Despite the obvious benefits, the vaccines may not be an easy sell: There are social and moral hurdles to overcome. |
American Family Physician
July 1, 2000
Monica Preboth |
Practice Guidelines ACIP Issues Recommendations for the 2000-2001 Influenza Season |
Scientific American
November 2008
Jessica Wapner |
Cancer Vaccine: Looking Beyond Tumor Size Proponents see hope in changing cancer vaccines' bad reputation |
Salon.com
December 15, 2000
Arthur Allen |
Warming to malaria With fears mounting that global climate change may cause the dreaded disease to spread, scientists turn their attention to vaccine research... |
BusinessWeek
October 25, 2004
John Carey |
A Booster Shot For Vaccines New technology could speed the development of vaccines and keep the medicine chest stocked. |
Wired
September 2002
Amanda Griscom |
Take These Genes and Call Me in the Morning Gene vaccines may be relatively new, but they're the logical outgrowth of two familiar strands of medical science. |
American Family Physician
July 1, 2004
Lo Re & Gluckman |
Travel Immunizations The approach to vaccine recommendations should be based on a thorough assessment of the risks for travel-related diseases, the time available before trip departure, and current knowledge of the epidemiology of vaccine-preventable diseases. |
BusinessWeek
October 22, 2007
Catherine Arnst |
Roll Up Your Sleeve, Gramps A graying population may create a huge market for vaccines that buttress aging immune systems. |
American Family Physician
January 1, 2004 |
Hepatitis B Infection What is hepatitis B virus?... How can I tell if I have HBV infection?... What happens after HBV infection?... What health problems can chronic HBV infection cause?... How can I protect my liver if I have chronic HBV infection?... How can HBV infection be prevented?... etc. |
BusinessWeek
November 28, 2005
Kerry Capell |
High-Velocity Vaccines PowderMed says its DNA technology would let it react quickly to a flu pandemic. A DNA flu vaccine would have huge advantages over traditional ones. But first, the company must prove in upcoming large-scale clinical trials that its vaccine can protect people from flu generally. |
Fast Company
June 2015 |
Meet Ebola's Soft-Spoken, Plant-Loving Arch Nemesis A professor at Arizona State University, Arntzen is considered the godfather of a growing field of research sometimes called "pharming": engineering plants to produce specialized vaccines and other drugs. |
BusinessWeek
October 24, 2005
John Carey |
New Vaccines For A Pandemic Using DNA, vast amounts of flu vaccine could be made quickly. But will the drugs work? |
American Family Physician
May 15, 2001 |
Pneumococcal Conjugate Vaccine: What a Parent Needs to Know Why should my child get this vaccine?... What exactly is the pneumococcal vaccine?... Are there some children who should not get pneumococcal conjugate vaccine or who should wait until they are older?... |
Managed Care
September 2006
Thomas Morrow |
Remarkable Work Went Into Designing the New HPV Vaccine The recently approved human papillomavirus vaccine is a prime example of how science is beating back the advance of old diseases. |
Chemistry World
June 12, 2015
Christopher Barnard |
Drawing order from disorder to unravel Ebola's lethality The virulence of Ebola virus strains appears to be innately linked to the degree of disorder in proteins that form their nucleocapsids. |
The Motley Fool
December 19, 2005
Brian Gorman |
Developing Drug Markets Drug companies focusing on the developing world could see major payoffs. Asia, Africa, and Australia offer very significant opportunities for investors. |
Bio-IT World
June 15, 2003
Malorye Branca |
A View to a Kill Genomics, bioinformatics, and novel laboratory techniques are converging to boost vaccine research against a new wave of emerging diseases, natural and man-made. Now, will in silico modeling ramp up sufficiently to further speed vaccine discovery? |
The Motley Fool
August 20, 2007
Brian Orelli |
Contracts That Are for the Birds Baxter and GlaxoSmithKline get bird flu vaccine contracts from the U.K. These contracts aren't reasons by themselves to run out and buy the companies' stock, but expanding income sources are almost always a good sign. |
Chemistry World
January 16, 2011
Hayley Birch |
Antibodies could lead to MRSA vaccine US scientists have developed antibodies against a protein belonging to methicillin-resistant Staphylococcus aureus bacteria. |
The Motley Fool
May 31, 2006
Stephen D. Simpson |
Vical Gets a Helping Hand Japan's AnGes MG's Allovectin-7 vaccine is now a risk-free lottery ticket for Vical. If phase 3 trials show adequate efficacy, there's upside. If the trials fail, Vical really doesn't lose much of anything. Investors, take note. |
BusinessWeek
February 4, 2010
Weintraub et al. |
Swine Flu: The Pandemic That Wasn't Swine flu is waning, but the lessons of H1N1 could come in handy during a more serious epidemic. |
American Family Physician
January 15, 2004 |
Influenza Vaccine What is influenza?... Who is at higher risk?... What is the flu vaccine?... Is the vaccine safe?... etc. |
Health
October 2007
Sarah Clachar |
Read this BEFORE you get a flu shot The flu vaccine may not be as good -- or as safe -- as you think. |
